Search

Search Constraints

You searched for: Author/Creator Shapiro, Julia

Search Results

1. Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis. Issue 6 (30th January 2022)

2. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. (October 2022)

3. Prostate‐specific membrane antigen positron emission tomography‐computed tomography use prior to systemic therapy in metastatic castration‐resistant prostate cancer. (30th November 2022)

4. Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?. (7th February 2023)

5. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study. (November 2021)

6. Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer. Issue 3 (14th December 2021)

7. Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer. Issue Volume 128:Issue Supplement 1(2021) (7th October 2021)

8. Treatment and outcomes of unresectable and metastatic pancreatic cancer treated in public and private Australian hospitals. Issue 4 (23rd November 2021)

9. Treatment outcomes for patients with metastatic castrate‐resistant prostate cancer following docetaxel for hormone‐sensitive disease. Issue 1 (24th September 2020)